Johnson & Johnson sought FDA approval for TREMFYA via sBLA, involving Dr. Philip J. Mease and the University of Washington School of Medicine in Seattle.
1 report, 1 independent
Updated May 28
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Johnson & Johnson sought FDA approval for TREMFYA via sBLA, involving Dr. Philip J. Mease and the University of Washington School of Medicine in Seattle.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Tremfya is gaining traction among US gastroenterologists due to its strong efficacy and safety profile, leading to increased market share against older TNF inhibitors.Sub-event
J&J seeks FDA approval for TREMFYA via sBLA, leveraging UoW expertise in Seattle.1 source
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
University of Washington School of Medicine
medical school
Nothing else this week.
- FDA